Accera Presents New Pharmacogenomics Data on Medical Food Product for Alzheimer's Disease

Accera presented data at the International Conference on Alzheimer's Disease this week in Vienna, showing that the ketogenic compound Axona "demonstrated significant improvement" in patients who lacked the epsilon 4 variant of the APOE gene and the C/C polymorphism in IDE 7.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.